

# Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes

Iziah E. Sama  and Adriaan A. Voors  \*

Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

Online publish-ahead-of-print 20 June 2020

**This commentary refers to ‘Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease’, by I.M. Schmidt et al., doi: 10.1093/eurheartj/ehaa523.**

In the commentary entitled ‘Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease’, Schmidt et al.<sup>1</sup> corroborate our work on plasma angiotensin-converting enzyme 2 (ACE2) levels in heart failure patients<sup>2</sup> by extending it to patients with kidney diseases. They did this by measuring plasma ACE2 levels from 551 patients in the Boston Kidney Biopsy Cohort<sup>3</sup> and came to similar conclusions that (i) higher plasma ACE2 is observed in men than women; (ii) in those with diabetes; and (iii) do not appear to be increased by use of angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker (ACE-I/ARB). Interestingly, it is now known that the use of ACE-I/ARB is not positively associated with mortality in COVID-19 patients.<sup>4</sup>

In a sub-analysis wherein we pooled both cohorts of our study, male sex, renal disease, diabetes, blood glucose, and glycated HbA1c were significantly more predominant ( $P < 0.05$ ) in the group of patients with elevated ( $\geq$ median) compared to low ( $<$ median) plasma ACE2 concentrations; further reinforcing the work of Schmidt et al.

## Funding

This work was supported by the European Commission (FP7-242209-BIOSTAT-CHF).

**Conflict of interest:** none declared.

## References

- Schmidt IM, Verma A, Waikar SS. Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease. *Eur Heart J* 2020;doi:10.1093/eurheartj/ehaa523.
- Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, Rienstra M, Friedrich AW, Samani NJ, Ng LL, Dickstein K, Lang CC, Filippatos G, Anker SD, Ponikowski P, Metra M, van Veldhuisen DJ, Voors AA. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. *Eur Heart J* 2020;41:1810–1817.
- Srivastava A, Palsson R, Kaze AD, Chen ME, Palacios P, Sabbisetti V, Betensky RA, Steinman TI, Thadhani RI, McMahon GM, Stillman IE, Rennke HG, Waikar SS. The prognostic value of histopathologic lesions in native kidney biopsy specimens: results from the Boston Kidney Biopsy Cohort Study. *J Am Soc Nephrol* 2018;29:2213–2224.
- Mancia G, Rea F, Luderghani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. *N Engl J Med* 2020; NEJMoa2006923. doi:10.1056/NEJMoa2006923.

\*Corresponding author. Tel: +31 (0)50 3616161, Fax: +31 (0)50 3618062, Email: [a.a.voors@umcg.nl](mailto:a.a.voors@umcg.nl)

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)